Literature DB >> 17012897

Dose-response relationship of DNA and recombinant fowlpox virus prime-boost HIV vaccines: implications for future trials.

Robert De Rose1, Mark T Sullivan, C Jane Dale, Anthony D Kelleher, Sean Emery, David A Cooper, Ian A Ramshaw, David B Boyle, Stephen J Kent.   

Abstract

Estimating effective doses of novel HIV vaccines is challenging. Dose-response analyses of DNA and fowlpox virus HIV vaccines showed that 1 mg of DNA vaccine and 5 x 10(7)pfu of fowlpox virus booster was immunogenic in macaques. However, this dose was poorly immunogenic in humans. When adjusted for body surface area, the human dose studied was equivalent to a poorly immunogenic lower dose in monkeys. These data provide a rationale for guiding dosing in future trials of HIV vaccine technologies.

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 17012897     DOI： 10.4161/hv.2940

Source DB:  PubMed          Journal:  Hum Vaccin        ISSN： 1554-8600


  4 in total

1.  Comparative efficacy of subtype AE simian-human immunodeficiency virus priming and boosting vaccines in pigtail macaques.

Authors:  Robert De Rose; C Jane Batten; Miranda Z Smith; Caroline S Fernandez; Viv Peut; Scott Thomson; Ian A Ramshaw; Barbara E H Coupar; David B Boyle; Vanessa Venturi; Miles P Davenport; Stephen J Kent
Journal:  J Virol       Date:  2006-10-18       Impact factor: 5.103

2.  An HIV-1 clade A/E DNA prime, recombinant fowlpox virus boost vaccine is safe, but non-immunogenic in a randomized phase I/IIa trial in Thai volunteers at low risk of HIV infection.

Authors:  Atchriya Hemachandra; Rebekah L Puls; Sunee Sirivichayakul; Stephen Kerr; Pattarawat Thantiworasit; Sasiwimol Ubolyam; David A Cooper; Sean Emery; Praphan Phanuphak; Anthony Kelleher; Kiat Ruxrungtham
Journal:  Hum Vaccin       Date:  2010-10-01

3.  A comparative analysis of HIV-specific mucosal/systemic T cell immunity and avidity following rDNA/rFPV and poxvirus-poxvirus prime boost immunisations.

Authors:  Charani Ranasinghe; Fiona Eyers; John Stambas; David B Boyle; Ian A Ramshaw; Alistair J Ramsay
Journal:  Vaccine       Date:  2011-02-23       Impact factor: 3.641

4.  Cross-species prophylactic efficacy of Sm-p80-based vaccine and intracellular localization of Sm-p80/Sm-p80 ortholog proteins during development in Schistosoma mansoni, Schistosoma japonicum, and Schistosoma haematobium.

Authors:  Adebayo J Molehin; Souad R Sennoune; Weidong Zhang; Juan U Rojo; Arif J Siddiqui; Karlie A Herrera; Laura Johnson; Justin Sudduth; Jordan May; Afzal A Siddiqui
Journal:  Parasitol Res       Date:  2017-10-12       Impact factor: 2.289
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.